The work of SymBio Pharmaceuticals capitalizes on existing cutting-edge research and technologies in order to spur the clinical development and launch of sought after drug therapies in Japan.
Prominent clinical physicians and scientists, with track records of success and a wealth of experience in wide-ranging disciplines related to drug development, serve as advisors at SymBio. Together, the SAB and Senior Advisors render crucial decisions on SymBio's next drug targets and definitive steps to be taken, with the underlying goal of addressing Enderserved medical needs' in Japan and other Asia-Pacific countries such as China, Korea, Taiwan and Singapore.
Chair: George Morstyn, M.D., Ph.D.
Robert Lewis, M.D., Ph.D.
Tomomitsu Hotta, M.D.
Makoto Ogawa, M.D., Ph.D.
Tatsutoshi Nakahata, M.D., Ph.D.
Toshio Suda, M.D., Ph.D.
Tsutomu Takeuchi, M.D., Ph.D.
Toshio Heike, M.D., Ph.D.
Koichi Takahashi, MD
Mathias J. Rummel, M.D., Ph.D.